Yuxin Mu

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 7

Top Topics

Combination Therapy

Newly Diagnosed

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Journal of cancer research and clinical oncology

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Yuxin Mu, Xuezhi Hao, Ke Yang, Di Ma, Shouzheng Wang, Ziyi Xu, Junling Li, Pu-Yuan Xing
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Targeted oncology 14 (3) (2020)
Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Teng Li, Jinyao Zhang, Ziyi Xu, Jun-Ling Li
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of cancer research and clinical oncology 146 (9) (2020)
Hongge Liang, Xia Song, Yuhui Zhang, Shucai Zhang, Fang Li, Jian Fang, Junling Li, Li Liang, Ligong Nie, Kewei Ma, Liangming Zhang, Xiaohong Wang, Junjun Xu, Yanxia Wei, Jinghui Wang, Qi Song, Guangming Tian, Yuxin Mu, Yangchun Gu, Lei Yang, Ping Sun, Wei Zhong, Jing Zhao, Yan Xu, Minjiang Chen, Mengzhao Wang
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. Thoracic cancer 10 (7) (2019)
Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Jun-Ling Li
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic cancer 10 (6) (2019)
Puyuan Xing, Yuxin Mu, Yan Wang, Xuezhi Hao, Yi-Xiang Zhu, Xingsheng Hu, Hongyu Wang, Peng Liu, Lin Lin, Zhijie Wang, Junling Li
Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. Thoracic cancer 9 (12) (2018)
Puyuan Xing, Yuxin Mu, Yan Wang, Xuezhi Hao, Yi-Xiang Zhu, Xingsheng Hu, Hongyu Wang, Peng Liu, Lin Lin, Zhijie Wang, Junling Li
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. Thoracic cancer 9 (7) (2018)